Business Wire

Pyramid Analytics added to the DoD’s Tradewind Solutions Marketplace

8.6.2023 16:07:00 EEST | Business Wire | Press release

Share

Pyramid Analytics (Pyramid), a leading business analytics and decision intelligence provider, is pleased to announce that its Pyramid Decision Intelligence Platform has been added to the Tradewind Solutions Marketplace, DoD’s digital environment of post-competition, readily awardable, technology solution pitch videos. The Tradewind Solutions Marketplace is the flagship offering of Tradewind, DoD’s suite of tools and services designed to accelerate the procurement and adoption of AI/ML, digital, and data analytics solutions across the DoD. Tradewind sits in the DoD’s Chief Digital Artificial Intelligence Office (CDAO).

The Pyramid Platform provides comprehensive, advanced analytics capabilities, including data pipelines and preparation (with embedded machine learning), enterprise and self-service data analytics, dashboarding (with built-in AI and chat-bots), and data science.

Pyramid’s platform was rated as “Awardable” and added to the Tradewind Solutions Marketplace. Solutions selected for the Marketplace, including the Pyramid Decision Intelligence Platform, have been assessed and vetted through competitive procedures, which satisfy the competition requirements of the Federal Acquisition Regulation (FAR), the Defense Federal Acquisition Regulation Supplement (DFARS), and the Statutes, Policies, and guidance applicable to the DoD’s Other Transaction Authorities.

Key points

  • Pyramid’s platform is now listed on the Tradewind Solutions Marketplace, DoD’s digital platform for sourcing AI/ML, digital, and data analytics solutions.
  • The DoD and the broader Defense Industrial Base has continued needs for low-code/no-code solutions that provide advanced analytics visualizations, machine learning, self-service analytics, natural language queries, and augmented and artificial intelligence.
  • The Pyramid Platform received top ratings in leading analyst firm Gartner’s 2023 Critical Capabilities for Analytics and Business Intelligence Platforms report, including #1 for Business Analyst Use Case, #1 for Augmented Consumer Use Case, #2 for Data Scientist Use Case, and #4 for Analytics Developer Use Case.
  • Pyramid’s US Federal Practice is led by a team of experienced leaders, including Joe Fritsch, Director of Federal Sales; Peter Morris, Senior Director of Partner Channel, North America; Dave Henry, Senior Vice President, Strategic Alliances; Russ Cosentino, Regional Vice President Sales, North America, East; and Brian McCormac, Senior Vice President of Global Sales.

“Being added to the Tradewind Solutions Marketplace is a significant recognition of the quality and relevance of our platform to the current and future needs of the defense industry. The Pyramid Decision Intelligence Platform offers comprehensive capabilities to support government agencies’ AI/ML, digital, and data analytics needs, enabling them to make faster and more informed decisions,” said Joe Fritsch, Director of Federal Sales at Pyramid Analytics.

In October 2022, Pyramid announced a new business practice dedicated to the US federal market, led by Joe Fritsch, and a strategic partnership with Carahsoft, The Trusted Government IT Solutions Provider®. This new DoD marketplace listing has strengthened its commitment to providing critical decision intelligence to government agencies.

The Pyramid Decision Intelligence Platform is already used by other government agencies, including the U.S. Department of Veterans Affairs, where it provides advanced analytics capabilities to over 50,000 users to help the VA manage, assess, and deliver quality healthcare to veterans across all VA hospitals.

Pyramid’s addition to the Tradewind Solutions Marketplace marks another significant milestone in the company’s dedication to helping U.S. federal civilian, defense, and intelligence agencies expand and optimize their use of data-informed decision intelligence at scale.

About Pyramid Analytics

Pyramid Analytics is the next generation of decision intelligence. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Platform operates directly on any data, enabling governed self-service for any person; and meeting analytical needs in a no-code environment without data extraction, ingestion, and duplication. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo today.

Pyramid Analytics USA is the U.S.-based subsidiary of Pyramid Analytics B.V. that is incorporated in Amsterdam with regional operations in global innovation and business centers, including New York City, London, and Tel Aviv. Our team lives worldwide because geography should not hinder talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.

For additional information on the Pyramid offerings in the Tradewind Solutions Marketplace, interested Government parties can log in at https://www.tradewindai.com/ and search for “Pyramid Analytics.” Registration is required.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Pyramid Analytics
Pete Vomocil
SVP, Global Marketing, Pyramid Analytics
pr@pyramidanalytics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye